Rentero Maria Luz, Amigo Encarna, Chozas Nicolas, Fernández Prada Manuel, Silva-Fernández Lucia, Abad Hernandez Miguel Angel, Rodriguez Barrera Jose Maria, del Pino-Montes Javier
Eli Lilly and Company, C/ Rey Francisco 11, 28008, Madrid, Spain.
Hospital de Lugo, San Cibrao, s/n, 27003, Lugo, Spain.
BMC Musculoskelet Disord. 2015 Oct 15;16:300. doi: 10.1186/s12891-015-0733-9.
Glucocorticoid (GC) therapy is associated with an increased risk of fractures. The main objective of this study was to determine the prevalence of undiagnosed vertebral fractures in women chronically using GC therapy for autoimmune disorders. We also determined the prevalence of non-vertebral fractures, and investigated whether factors such as quality-of-life and future fracture risk are associated with vertebral/non-vertebral fractures.
This was a multicenter cross-sectional study conducted in Spain. All women had rheumatoid arthritis (RA) and/or systemic lupus erythematosus (SLE). Radiological morphometric vertebral fractures were evaluated centrally (Genant semiquantitative method), whereas non-vertebral fractures were not assessed by radiography. Before radiography, patients were asked whether they had vertebral/non-vertebral fractures, hereafter referred to as 'self-reported' fractures. Assessment tools included the Disease Activity Score (DAS28), the SF-36 questionnaire, and FRAX®.
Complete data were obtained for 576 outpatients with RA and/or SLE (83.3 % had RA); mean [SD] age 59.6 [15] years. Of all patients, 6.4 % had self-reported vertebral fractures, whereas 18.9 % had morphometric vertebral fractures (RA: 7.1 % self-reported vs. 20.0 % morphometric; SLE: 3.2 % self-reported vs. 13.7 % morphometric). Non-vertebral fractures were self-reported by 9.8 % of RA and 5.3 % of SLE patients. Low physical functioning was associated with morphometric vertebral fractures (mean [SD] SF-36 score 18.8 [6.0] when present vs. 20.1 [5.9] when absent; p = 0.028) and self-reported non-vertebral fractures (16.7 [5.2] when present vs. 20.1 [5.9] when absent; p < 0.001). Mean [SD] DAS28 was higher (p = 0.013) when any self-reported fractures were present (4.0 [1.3]) than absent (3.6 [1.3]). Based on FRAX® analysis, patients with vs. without morphometric vertebral fractures had higher 10-year probabilities of major osteoporotic fractures (mean [SD] 17.9 [12.9]% vs. 9.9 [9.6]%; p < 0.001) and hip fractures (11.0 [11.7]% vs. 4.6 [8.1]%; p < 0.001).
Morphometric vertebral fractures were detected in 18.9 % of patients, i.e. 3-times more frequently than verbally reported by patients. Patients with vs. without fractures had worse quality-of-life and increased fracture risk. Accordingly, it is of utmost importance that women chronically using GCs are assessed for fractures, including morphometric vertebral fractures.
糖皮质激素(GC)治疗与骨折风险增加相关。本研究的主要目的是确定长期使用GC治疗自身免疫性疾病的女性中未诊断出的椎体骨折的患病率。我们还确定了非椎体骨折的患病率,并调查了生活质量和未来骨折风险等因素是否与椎体/非椎体骨折相关。
这是一项在西班牙进行的多中心横断面研究。所有女性均患有类风湿性关节炎(RA)和/或系统性红斑狼疮(SLE)。通过集中评估(Genant半定量法)对放射学形态计量学椎体骨折进行评估,而非椎体骨折未通过X线摄影进行评估。在进行X线摄影之前,询问患者是否有椎体/非椎体骨折,以下称为“自我报告”骨折。评估工具包括疾病活动评分(DAS28)、SF-36问卷和FRAX®。
共获得576例RA和/或SLE门诊患者的完整数据(83.3%患有RA);平均[标准差]年龄59.6[15]岁。在所有患者中,6.4%有自我报告的椎体骨折,而18.9%有形态计量学椎体骨折(RA:自我报告的为7.1%,形态计量学的为20.0%;SLE:自我报告的为3.2%,形态计量学的为13.7%)。9.8%的RA患者和5.3%的SLE患者自我报告有非椎体骨折。身体功能低下与形态计量学椎体骨折相关(存在时SF-36平均[标准差]评分为18.8[6.0],不存在时为20.1[5.9];p = 0.028)以及自我报告的非椎体骨折相关(存在时为16.7[5.2],不存在时为20.1[5.9];p < 0.001)。当存在任何自我报告的骨折时,平均[标准差]DAS28更高(p = 0.013)(4.0[1.3]),而不存在时为(3.6[1.3])。基于FRAX®分析,有形态计量学椎体骨折的患者与无骨折的患者相比,发生主要骨质疏松性骨折的10年概率更高(平均[标准差]为17.9[12.9]%对9.9[9.6]%;p < 0.001),髋部骨折的概率也更高(11.0[11.7]%对4.6[8.1]%;p < 0.001)。
18.9%的患者检测到形态计量学椎体骨折,即比患者口头报告的频率高3倍。有骨折与无骨折的患者相比,生活质量更差且骨折风险增加。因此,对长期使用GC的女性进行骨折评估,包括形态计量学椎体骨折评估极为重要。